Esperion Therapeutics Stock Investor Sentiment

ESPR Stock  USD 2.21  0.05  2.21%   
Slightly above 67% of Esperion Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Esperion Therapeutics suggests that many traders are alarmed. Esperion Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Esperion Therapeutics. Many technical investors use Esperion Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  

Esperion Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Esperion Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Esperion Therapeutics Maximum Pain Price Across March 21st 2025 Option Contracts

Esperion Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Esperion Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Esperion Therapeutics' options.
few days ago at zacks.com         
Ardelyx Moves 16.0 percent Higher Will This Strength Last?
zacks News
over a week ago at finance.yahoo.com         
Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 1130 a.m. ET.
Yahoo News
over a week ago at gurufocus.com         
Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 1130 a.m. ET.
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
Gurufocus Stories at Macroaxis
over two weeks ago at news.google.com         
Short Interest in Esperion Therapeutics, Inc. Decreases By 16.5 percent - MarketBeat
Google News at Macroaxis
over three weeks ago at www.macroaxis.com         
Acquisition by Benjamin Looker of 20500 shares of Esperion Therapeutics subject to Rule 16b-3
Macroaxis News
over three weeks ago at news.google.com         
ESPR - Esperion Therapeutics, Inc. Latest Stock News Market Updates - StockTitan
Google News at Macroaxis
over three weeks ago at thelincolnianonline.com         
Cantor Fitzgerald Begins Coverage on Esperion Therapeutics
news
over a month ago at thefly.com         
Esperion reinstated with a Neutral at Goldman Sachs ESPR
news
over a month ago at investing.com         
Esperion Therapeutics issues 100M in new convertible notes
Investing News at Macroaxis
over a month ago at investing.com         
Disposition of 3245 shares by Halladay Benjamin of Esperion Therapeutics at 2.424 subject to Rule 16...
Investing News at Macroaxis
over a month ago at globenewswire.com         
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
Macroaxis News: globenewswire.com
over a month ago at www.macroaxis.com         
Disposition of 12447 shares by Sheldon Koenig of Esperion Therapeutics at 2.466 subject to Rule 16b-...
Macroaxis News
over a month ago at seekingalpha.com         
Esperion announces 210M convertible debt financing
seekingalpha News
over a month ago at gurufocus.com         
Esperion Announces 210 Million Convertible Debt Financing
Gurufocus Stories at Macroaxis
Far too much social signal, news, headlines, and media speculation about Esperion Therapeutics that are available to investors today. That information is available publicly through Esperion media outlets and privately through word of mouth or via Esperion internal channels. However, regardless of the origin, that massive amount of Esperion data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Esperion Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Esperion Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Esperion Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Esperion Therapeutics alpha.

Esperion Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Esperion to Report Third Quarter 2024 Financial Results on November 7
10/24/2024
2
Esperion Therapeutics Growth Initiatives Are Paying Off - Buy - Seeking Alpha
11/13/2024
3
Disposition of 197 shares by Warren Eric of Esperion Therapeutics at 2.165 subject to Rule 16b-3
11/19/2024
4
ESPR Files New Drug Submissions for Nexletol Nexlizet in Canada
12/03/2024
5
Parkman Healthcare Partners LLC Has 1.49 Million Stock Holdings in Esperion Therapeutics, Inc.
12/04/2024
6
Esperion Partners with Neopharm to Commercialize NEXLETOL and NEXLIZET in Israel
12/12/2024
7
Esperion announces 210M convertible debt financing
12/13/2024
8
Disposition of 12447 shares by Sheldon Koenig of Esperion Therapeutics at 2.466 subject to Rule 16b-3
12/17/2024
9
Disposition of 3245 shares by Halladay Benjamin of Esperion Therapeutics at 2.424 subject to Rule 16b-3
12/18/2024
10
ESPR - Esperion Therapeutics, Inc. Latest Stock News Market Updates - StockTitan
12/20/2024
11
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
01/02/2025
12
Ardelyx Moves 16.0 percent Higher Will This Strength Last
01/14/2025

Additional Tools for Esperion Stock Analysis

When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.